AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9013456
Drug: Deferred therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred therapy (Ganciclovir use)
Trial: 9013456
Drug: Preemptive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive therapy (CMV-associated charges)
Trial: 9013456
Drug: Deferred therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred therapy (CMV-associated charges)
Trial: 6374539
Drug: Intravenous normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous normal saline
Trial: 26747128
Drug: modified constraint‐induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified constraint‐induced movement therapy (mCIMT) for 3 weeks
Trial: 19666912
Drug: Early immunosuppressive
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early immunosuppressive therapy (cyclophosphamide for 12 months, and steroids)
Trial: 19666912
Drug: Late immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late immunosuppressive therapy (initiated when renal function deteriorated)
Trial: 16479390
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (split GFR between 20 and 30 ml/min)
Trial: 15364875
Drug: TP10 (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TP10 (1, 3, 5, 10 mg/kg)
Trial: 8841220
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of oral ketoprofen preoperatively and mesosalpinx infiltration with 5 mL of saline plus epinephrine 1:200,000
Trial: 8841220
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of oral ketoprofen preoperatively and mesosalpinx infiltration with 5 mL of bupivacaine 0.5% with epinephrine 1:200,000
Trial: 8841220
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule with mesosalpinx infiltration
Trial: 8841220
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of preoperative ketoprofen and mesosalpinx block
Trial: 6741677
Drug: Program adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Program adherence post-treatment
Trial: 30922101
Drug: Repeated ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated ketamine infusions (six infusions administered thrice weekly over 2 weeks)
Trial: 30922101
Drug: Weekly maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly maintenance infusions (four additional infusions administered once weekly)
Trial: 28854569
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition (no additional treatment, n = 235)
Trial: 24843653
Drug: cilnidipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilnidipine (10 mg/day)
Trial: 21906391
Drug: azelnidipine (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: azelnidipine (16 mg/day)
Trial: 16625987
Drug: Generic efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic efavirenz capsule (Ranbaxy-Efavirenz)
Trial: 16625987
Drug: Innovator efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Innovator efavirenz capsule (Sustiva)
Trial: 15541407
Drug: Buccal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal misoprostol (600 microg)
Trial: 8329255
Drug: Metoclopramide 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 0.5 mg kg‐1
Trial: 3539508
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg PGE2 methyl sulphonylamide
Trial: 3539508
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg PGE1 methyl ester
Trial: 3539508
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg 9-methylene PGE2 free acid
Trial: 3539508
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg 15-methyl PGF2 alpha
Trial: 19065890
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of Shehuang Paste (SHP) and colonic dialysis with herbal medicine
Trial: 19065890
Drug: Conventional basic
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional basic therapy (placebo paste and colonic dialysis with normal saline)
Trial: 12587536
Drug: Dopamine-agonist therapy
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine-agonist therapy
Trial: 12587536
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (healthy controls and dopamine-agonist treated women)
Trial: 7640116
Drug: Tenoxicam 20
RxNorm normalized name: tenoxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 20 mg i.v. given 10 min before induction of anaesthesia
Trial: 7640116
Drug: Tenoxicam 20
RxNorm normalized name: tenoxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 20 mg i.v. group
Trial: 797447
Drug: Dianhydrogalactitol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dianhydrogalactitol (30 mg/m2/day for 5 days)
Trial: 797447
Drug: VP-16-213 (130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VP-16-213 (130 mg/m2 on Days 1, 3, and 5)
Trial: 31484582
Drug: Conventional administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional administration of oxygen through a Venturi mask (Control)
Trial: 28504995
Drug: Control therapy
RxNorm normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control therapy without RIPC
Trial: 25888246
Drug: HER2+ hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HER2+ hormone receptor-positive (HR+) patients
Trial: 25888246
Drug: HER2+ hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HER2+ hormone receptor-negative (HR-) patients
Trial: 23503449
Drug: Fasting conditions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting conditions (400 mg posaconazole)
Trial: 23503449
Drug: Normal-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-fat meal (400 mg posaconazole)
Trial: 23503449
Drug: High-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat meal (400 mg posaconazole)
Trial: 11126352
Drug: Family therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family therapy as part of an intervention program for childhood obesity, including behavior modification.
Trial: 9004827
Drug: Actuarial approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actuarial approach to treatment benefits
Trial: 31712013
Drug: Prostaglandin analogue
RxNorm normalized name: Prostaglandin analogue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin analogue (PGA) monotherapy (control group)
Trial: 31712013
Drug: Washout group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Washout group (discontinue PGA monotherapy)
Trial: 24573586
Drug: Simple ligation
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple ligation of the saphenous vein without sectioning of its arch (Group L)
Trial: 12875580
Drug: Betahistine (BH)
RxNorm normalized name: betahistine
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine (BH) 48 mg daily
Trial: 12875580
Drug: Flunarizine (FL)
RxNorm normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine (FL) 10 mg daily
Trial: 8854285
Drug: Essential fatty
RxNorm normalized name: essential fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential fatty acids (EFA) supplementation (Linoleic acid 596 mg/day and alpha-linolenic acid 855 mg/day)
Trial: 25789633
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin (ASA) prophylaxis
Trial: 25789633
Drug: Control event
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Control event rate (CERmin) and minimum event rate for treatment (MERT) approaches
Trial: 11004426
Drug: Diamicron(R)MR (30-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diamicron(R)MR (30-120 mg/day)
Trial: 11004426
Drug: Diamicron(R) (80-320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diamicron(R) (80-320 mg/day)
Trial: 8608520
Drug: Imipenem plus
RxNorm normalized name: Imipenem
DrugBank: Imipenem (DB01598)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Imipenem plus vancomycin (500 mg every 6 hours of imipenem/cilastatin and 1 g every 12 hours of vancomycin)
Trial: 8608520
Drug: Aztreonam plus
RxNorm normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aztreonam plus vancomycin (2 g every 6 hours of aztreonam and 1 g every 12 hours of vancomycin)
Trial: 31818409
Drug: Isatuximab plus
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Isatuximab plus pomalidomide and low‐dose dexamethasone
Trial: 31818409
Drug: Pomalidomide and
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide and low‐dose dexamethasone
Trial: 15207416
Drug: Risperidone 1
RxNorm normalized name: risperidone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 1 mg daily (in divided doses)
Trial: 15207416
Drug: Olanzapine 5
RxNorm normalized name: olanzapine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 5 mg at bedtime
Trial: 15207416
Drug: Promazine 50
RxNorm normalized name: promazine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promazine 50 mg daily (in divided doses)
Trial: 7976645
Drug: High oncotic
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High oncotic pressure (HOP; 26‐30 mmHg) treatment
Trial: 7976645
Drug: Normal oncotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal oncotic pressure (NOP; 22‐26 mmHg) treatment
Trial: 2917587
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg pipequaline
Trial: 1101902
Drug: Diphenoxylate 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenoxylate 5 mg single oral dose
Trial: 21453467
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc sulfate-topical corticosteroid combination
Trial: 19700948
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomoxetine (ATX) 25-80 mg/day
Trial: 15307699
Drug: Luohuo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luohuo capsule (LHC)
Trial: 11175492
Drug: Etofibrate (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etofibrate (500 mg twice daily)
Trial: 11175492
Drug: Controlled-release niacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release niacin (500 mg twice daily)
Trial: 27269043
Drug: ubrogepant 25
RxNorm normalized name: Ubrogepant
DrugBank: Ubrogepant (DB15328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ubrogepant 25 mg
Trial: 20722676
Drug: Lixisenatide 5
RxNorm normalized name: LIXISENATIDE 50/100MCG/MLX3ML START KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide 5 microg once daily
Trial: 20722676
Drug: Lixisenatide 10
RxNorm normalized name: LIXISENATIDE 100MCG/ML INJ,SOLN,PEN,3ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide 10 microg once daily
Trial: 20722676
Drug: Lixisenatide 20
RxNorm normalized name: lixisenatide 20 mcg/0.2 mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide 20 microg once daily
Trial: 20722676
Drug: Lixisenatide 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide 30 microg once daily
Trial: 20722676
Drug: Lixisenatide 5
RxNorm normalized name: LIXISENATIDE 50/100MCG/MLX3ML START KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide 5 microg twice daily
Trial: 20722676
Drug: Lixisenatide 10
RxNorm normalized name: LIXISENATIDE 100MCG/ML INJ,SOLN,PEN,3ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide 10 microg twice daily
Trial: 20722676
Drug: Lixisenatide 20
RxNorm normalized name: lixisenatide 20 mcg/0.2 mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide 20 microg twice daily
Trial: 20722676
Drug: Lixisenatide 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide 30 microg twice daily
Trial: 18401602
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine digluconate gel (CHX)
Trial: 16372263
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin C supplementation (250 mg three times per week)
Trial: 11113618
Drug: Novel antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel antioxidant supplements
Trial: 9026680
Drug: Bed-time ultralente
RxNorm normalized name: INSULIN,ULTRALENTE,HUMAN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bed-time ultralente insulin (0.15-0.2 U/kg)
Trial: 9026680
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin (0.15-0.2 U/kg)
Trial: 3370851
Drug: L‐menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐menthol
Trial: 30152415
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care group (PCG)
Trial: 23277307
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary intervention with drug eluting stents (DES-PCI)
Trial: 21623673
Drug: Somatostatin analog
RxNorm normalized name: Somatostatin analog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin analog (SA) treatment for 4 weeks
Trial: 19257967
Drug: Thymus mature
RxNorm normalized name: THYMUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymus mature dendritic cells (mDC) in MG patients
Trial: 11110851
Drug: Conjugated linoleic
RxNorm normalized name: CONJUGATED LINOLEIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated linoleic acid (3.4 g per day)
Trial: 11110851
Drug: Conjugated linoleic
RxNorm normalized name: CONJUGATED LINOLEIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated linoleic acid (6.8 g per day)
Trial: 11110851
Drug: Placebo (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (9 g olive oil)
Trial: 2186660
Drug: Oral diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diazepam (0.5 mg/kg)
Trial: 2186660
Drug: Oral trimeprazine
RxNorm normalized name: trimeprazine
DrugBank: Alimemazine (DB01246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral trimeprazine (4 mg/kg)
Trial: 2186660
Drug: Oral pentobarbitone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pentobarbitone (3 mg/kg)
Trial: 450929
Drug: Methamphetamine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methamphetamine (0.2 mg/kg or 0.3 mg/kg)
Trial: 31486832
Drug: Doxorubicin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (60 mg/m2 every 21 days) plus Sorafenib (400 mg orally twice daily)
Trial: 19619102
Drug: PHC-based interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHC-based interventions for unemployed people, details on dosage and duration not available.
Trial: 18035194
Drug: Topical ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ciprofloxacin 0.3%/dexamethasone 0.1% (CD) otic suspension
Trial: 18035194
Drug: Polymyxin B/neomycin/hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymyxin B/neomycin/hydrocortisone (PNH) otic suspension
Trial: 14709948
Drug: Quetiapine (200-1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (200-1200 mg/d)
Trial: 16709552
Drug: Risperidone (1-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (1-6 mg/d)
Trial: 7859241
Drug: Tosufloxacin 150
RxNorm normalized name: tosufloxacin
DrugBank: Tosufloxacin (DB16850)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tosufloxacin 150 mg orally three times daily
Trial: 7859241
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg orally twice daily
Trial: 29119733
Drug: Fentanyl 3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 3.5 μg/kg via slow intravenous fluid line
Trial: 29119733
Drug: Fentanyl 3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 3.5 μg/kg via direct injection (control group)
Trial: 23138961
Drug: Contingency management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingency management for stimulant abstinence plus treatment as usual
Trial: 23138961
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual with reinforcement for study participation only
Trial: 16968575
Drug: Rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 4 mg/day plus metformin 1000 mg/day (RSG + MET)
Trial: 16968575
Drug: Metformin 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1500 mg/day (up-titrated MET)
Trial: 9352145
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human erythropoietin (rhEPO) at dosages up to 300 U/kg thrice weekly for 12 weeks
Trial: 4065188
Drug: Femoxetine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoxetine (200 mg single dose)
Trial: 4065188
Drug: Amitriptyline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (50 mg single dose)
Trial: 4065188
Drug: Femoxetine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoxetine (600 mg/day for 10 days)
Trial: 4065188
Drug: Femoxetine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoxetine (600 mg/day for 10 days) with alcohol (EtOH)
Trial: 26630391
Drug: Clozapine treatment
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine treatment for 8 weeks
Trial: 25254301
Drug: Therapeutic rAd5
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic rAd5 HIV‐1 gag vaccine
Trial: 15121485
Drug: Aprepitant 30
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant 30 mg
Trial: 15121485
Drug: Aprepitant 100
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant 100 mg
Trial: 15121485
Drug: Aprepitant 300
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant 300 mg
Trial: 11673771
Drug: Test yoghurt
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test yoghurt (200 g portion containing 5 g of a novel fat emulsion + 1 g milk fat)
Trial: 7533904
Drug: Proteinase inhibitors
RxNorm normalized name: Proteinase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proteinase inhibitors
Trial: 2438874
Drug: 20% azelaic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% azelaic acid (AA) applied topically twice daily for 3 months
Trial: 27786359
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy plus usual care (n=123; 76 in final analyses)
Trial: 25810023
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg morphine administered per rectum
Trial: 25810023
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg MNTX given subcutaneously before 30 mg rectal morphine
Trial: 11403367
Drug: Irbesartan 150
RxNorm normalized name: irbesartan 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 150 mg q.d.
Trial: 3124618
Drug: Intranasal buserelin
RxNorm normalized name: buserelin
DrugBank: Buserelin (DB06719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal buserelin (400 micrograms 3 times a day)
Trial: 3124618
Drug: Subcutaneous buserelin
RxNorm normalized name: buserelin
DrugBank: Buserelin (DB06719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous buserelin injection (200 micrograms once daily)
Trial: 3124618
Drug: Intranasal and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal and subcutaneous buserelin